Current treatment for renal anemia is the use of ESAs, which they are associated with a number of adverse outcomes such as worsened hypertension and cardiovascular disease, thromboembolism, tumor growth, and resistance to Epo therapy itself (1, 3, 11–13, 59). The gene discussed is EPO; the disease is Thromboembolism.